靶向药物时代局部晚期甲状腺癌的新辅助治疗

外科理论与实践››2021,Vol. 26››Issue (06): 493-496.doi:10.16139/j.1007-9610.2021.06.006

靶向药物时代局部晚期甲状腺癌的新辅助治疗

黄乃思, 陈嘉莹, 嵇庆海, 王宇()

复旦大学附属肿瘤医院头颈外科复旦大学上海医学院肿瘤学系，上海 200032

收稿日期:2021-09-27出版日期:2021-11-25发布日期:2022-07-27
通讯作者:王宇 E-mail:neck130@hotmail.com
基金资助:
国家自然科学基金(82072951);国家自然科学基金青年项目(81902721);上海抗癌协会上海市科委西医引导项目(19411966600);上海市抗癌协会翱翔计划项目(SACA-AX106);上海申康医院发展中心项目(SHDC2020CR6003);上海市青年科技英才扬帆计划(19YF1409300)

New adjuvant treatment of locally advanced thyroid carcinoma in era of targeted therapy

HUANG Naisi, CHEN Jiaying, Jl Qinghai, QANG Yu()

Received:2021-09-27Online:2021-11-25Published:2022-07-27
Contact:QANG Yu E-mail:neck130@hotmail.com

摘要/Abstract

中图分类号:

R736.1

黄乃思, 陈嘉莹, 嵇庆海, 王宇. 靶向药物时代局部晚期甲状腺癌的新辅助治疗[J]. 外科理论与实践, 2021, 26(06): 493-496.

HUANG Naisi, CHEN Jiaying, Jl Qinghai, QANG Yu. New adjuvant treatment of locally advanced thyroid carcinoma in era of targeted therapy[J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 493-496.

图/表1

病理类型	基因状态	药物选择	常用药物
分化型甲状腺癌		多靶点酪氨酸激酶抑制剂	索拉非尼、仑伐替尼等
髓样癌	RET野生型	多靶点酪氨酸激酶抑制剂	安罗替尼、凡他尼布、卡博替尼等
	RET突变型	RET特异性抑制剂	塞尔帕替尼、普拉替尼
未分化癌	BRAF野生型	多靶点酪氨酸激酶抑制剂+/-PD1	法米替尼、阿帕替尼等
	BRAF突变型	BRAF抑制剂+MEK抑制剂+/-PD1	达拉非尼+曲美替尼

参考文献20

[1]	田文, 樊友本, 房居高, 等. 局部晚期甲状腺癌手术治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(4):369-376.
[2]	Wang LY, Nixon IJ, Patel SG, et al. Operative management of locally advanced, differentiated thyroid cancer[J]. Surgery, 2016, 160(3):738-746.
[3]	Chen W, Sun K, Zheng H, et al. Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1):1-12.
[4]	Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases[J]. J Clin Endocrinol Metab, 1999, 84(11):4043-4049.
[5]	Beasley NJ, Walfish PG, Witterick I, et al. Cause of death in patients with well-differentiated thyroid carcinoma[J]. Laryngoscope, 2001, 111(6):989-991.
[6]	Hartl DM, Zago S, Leboulleux S, et al. Resection margins and prognosis in locally invasive thyroid cancer[J]. Head Neck, 2014, 36(7):1034-1038.
[7]	Rubens RD, Sexton S, Tong D, et al. Combined chemotherapy and radiotherapy for locally advanced breast cancer[J]. Eur J Cancer, 1980, 16(3):351-356.
[8]	Tsuboi M, Takizawa H, Aoyama M, et al. Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: a case report[J]. Int J Surg Case Rep, 2017, 41:89-92.
[9]	Iwasaki H, Toda S, Ito H, et al. A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy[J]. Case Rep Endocrinol, 2020, 2020:6438352.
[10]	Stewart KE, Strachan MWJ, Srinivasan D, et al. Tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a case report[J]. Eur Thyroid J, 2019, 8(2):102-107.
[11]	Danilovic DLS, Castro G Jr, Roitberg FSR, et al. Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer[J]. Arch Endocrinol Metab, 2018, 62(3):370-375.
[12]	Nava CF, Scheffel RS, Cristo AP, et al. Neoadjuvant multikinase inhibitor in patients with locally advanced unresectable thyroid carcinoma[J]. Front Endocrinol (Lausanne), 2019, 10:712.
[13]	Cleary JM, Sadow PM, Randolph GW, et al. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib[J]. J Clin Oncol, 2010, 28(23):e390-e392.
[14]	Golingan H, Hunis B, Golding AC, et al. Neoadjuvant Lenvatinib in advanced unresectable medullary thyroid carcinoma: a case report[J]. AACE Clin Case Rep, 2019, 6(2):e73-e78.
[15]	Jozaghi Y, Zafereo M, Williams MD, et al. Neoadjuvant selpercatinib for advanced medullary thyroid cancer[J]. Head Neck, 2021, 43(1):E7-E12.
[16]	Cabanillas ME, Ferrarotto R, Garden AS, et al. Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma[J]. Thyroid, 2018, 28(7):945-951.
[17]	Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF^V600E-mutated anaplastic thyroid carcinoma[J]. Thyroid, 2019, 29(8):1036-1043.
[18]	Huang NS, Wei WJ, Xiang J, et al. The efficacy and safety of anlotinib in neoadjuvant treatment in locally advanced thyroid cancer: a single-arm phase Ⅱclinical trial[J]. Thyroid, 2021[online ahead of print].
[19]	Li D, Chi Y, Chen X, et al. Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase ⅡB trial[J]. Clin Cancer Res, 2021, 27(13):3567-3575.
[20]	Chi Y, Gao M, Zhang Y, et al. LBA 88 anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phaseⅡ trial[J]. Ann Oncol, 2020, 31(S4):S1215.

靶向药物时代局部晚期甲状腺癌的新辅助治疗

New adjuvant treatment of locally advanced thyroid carcinoma in era of targeted therapy

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表1

参考文献20

相关文章15

编辑推荐

Metrics

本文评价

[1]	贺文, 顾建华, 邢戌健, 翁子毅, 费健.术中发现气管憩室2例病例报告并文献复习[J]. 外科理论与实践, 2023, 28(04): 383-387.
[2]	邢颖, 程石.胆囊癌新辅助治疗的现状和争议[J]. 外科理论与实践, 2023, 28(02): 110-114.
[3]	高卫奇, 张旭, 王铮, 朱一霏, 黄佳慧, 洪进, 朱思吉, 陈小松, 黄欧, 何建蓉, 陈伟国, 李亚芬, 沈坤炜, 徐华, 吴佳毅.新辅助治疗后腹壁下深血管穿支皮瓣即刻乳房重建手术的安全性研究[J]. 外科理论与实践, 2023, 28(02): 147-151.
[4]	王远江, 邹浩.胆囊癌综合治疗的临床研究[J]. 外科理论与实践, 2023, 28(02): 171-176.
[5]	宋达疆　李赞　章一新.带蒂腹直肌皮瓣联合游离腹壁下动脉穿支皮瓣移植重建胸壁巨大缺损的手术策略[J]. 组织工程与重建外科杂志, 2022, 18(5): 386-.
[6]	陈小松, 沈坤炜, 李宏为.早期可手术乳腺癌的诊治现状与展望[J]. 外科理论与实践, 2022, 27(05): 385-386.
[7]	王杰强综述, 马德奎审校.Trop2基因与三阴性乳腺癌的研究进展[J]. 外科理论与实践, 2022, 27(05): 473-477.
[8]	张吉祥, 谢智华, 综述, 李炜, 姜小清, 审校.肝内胆管癌的分型和外科治疗热点[J]. 外科理论与实践, 2022, 27(05): 478-482.
[9]	郭杨, 郭天安, 徐烨.直肠癌新辅助化疗的研究进展[J]. 外科理论与实践, 2022, 27(04): 370-374.
[10]	李佳, 吕良敬.靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022, 21(03): 299-303.
[11]	许梓枫综述, 宗雅萍, 陆爱国审校.局部进展期结肠癌病人的新辅助治疗[J]. 外科理论与实践, 2022, 27(03): 266-270.
[12]	吴春晓, 顾凯, 庞怡, 鲍萍萍, 王春芳, 施亮, 向詠梅, 龚杨明, 窦剑明, 吴梦吟, 付晨, 施燕.2016年上海市甲状腺癌发病和死亡情况与2002—2016年间变化趋势分析[J]. 外科理论与实践, 2022, 27(01): 58-65.
[13]	唐娟, 刘志艳.第4版WHO分化型甲状腺癌病理分类及其进展[J]. 外科理论与实践, 2021, 26(06): 504-509.
[14]	詹灵(综述), 邱伟华(审校).阿帕替尼治疗放射性碘难治性与高度侵袭性甲状腺癌的研究进展[J]. 外科理论与实践, 2021, 26(06): 564-567.
[15]	姚京, 李晨, 田文.甲状腺癌的规范诊治[J]. 外科理论与实践, 2021, 26(06): 467-471.